Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TETRACHEL vs ACTISITE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
Infections caused by susceptible strains of Rickettsiae,Mycoplasma pneumoniae infections,Psittacosis (ornithosis),Chlamydia trachomatis infections (e.g., uncomplicated urethral, endocervical, rectal),Brucellosis (in conjunction with streptomycin),Chancroid,Granuloma inguinale,Lymphogranuloma venereum,Relapsing fever,Bartonellosis,Plague,Tularemia,Acute intestinal amebiasis (adjunctive therapy),Severe acne,Propionibacterium acnes infections,Off-label: Helicobacter pylori eradication (as part of quadruple therapy)
Treatment of periodontal disease (adjunct to scaling and root planing),Topical treatment of infected wounds and skin ulcers
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
Tetracycline is primarily metabolized in the liver via glucuronidation and undergoes enterohepatic circulation. Minor metabolism may involve microsomal enzymes.
Not significantly metabolized; primarily excreted unchanged in urine and feces.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
65% (primarily albumin).
Not applicable (no systemic absorption); if systemically present, tetracycline is 50-60% bound to plasma proteins.
1.3 L/kg (extensive tissue penetration, including bone and teeth).
Not applicable due to lack of systemic absorption; if systemic, tetracycline Vd is 1.3-1.6 L/kg.
Oral: 77-96% (decreased by food, dairy, antacids).
Negligible systemic bioavailability (<0.1%) when applied topically; not administered orally or intravenously for periodontal use.
Cr Cl >50 m L/min: no adjustment. Cr Cl 30-50 m L/min: 250 mg once daily. Cr Cl <30 m L/min: 125 mg once daily.
Not systemically absorbed; no renal adjustment required.
Child-Pugh A: no adjustment. Child-Pugh B: 250 mg once daily. Child-Pugh C: 125 mg once daily.
Not systemically absorbed; no hepatic adjustment required.
Children ≥8 years: 5 mg/kg orally once daily (max 500 mg) for 28 days.
Safety and efficacy not established in pediatric patients.
Initiate at low end of dosing range; monitor renal function and adjust dose based on Cr Cl.
No specific dose adjustment; use standard adult dosing with caution for age-related comorbidities.
Tetracycline can cause fetal harm when administered to a pregnant woman. Use during tooth development (last half of pregnancy, infancy, and children up to 8 years) may cause permanent discoloration of teeth (yellow-gray-brown). It should not be used in this age group unless other drugs are not likely to be effective or are contraindicated.
None
Photosensitivity: exaggerated sunburn reaction; avoid direct sunlight and UV light.,Hepatotoxicity: may cause liver damage, especially in patients with renal impairment or receiving high doses.,Renal impairment: accumulation may occur; dosage adjustment required.,Superinfection: use of tetracycline may result in overgrowth of non-susceptible organisms, including fungi.,Pseudomembranous colitis: Clostridium difficile-associated diarrhea has been reported.,Intracranial hypertension: bulging fontanelles in infants and benign intracranial hypertension in adults.,Tissue irritation: avoid extravasation; thrombophlebitis risk with IV administration.
Photosensitivity,Superinfection with resistant organisms,Use in renal impairment may require dose adjustment,Not recommended in children under 8 years due to permanent tooth discoloration
Hypersensitivity to tetracyclines or any component of the formulation.,Pregnancy (especially second and third trimesters) and lactation.,Children under 8 years of age (except for specific infections like anthrax or where no alternative exists).,Severe hepatic impairment.
Hypersensitivity to tetracyclines,Severe renal impairment
Avoid dairy products, calcium-fortified foods, and antacids containing calcium, magnesium, or aluminum, as they reduce absorption. Iron supplements, bismuth subsalicylate, and zinc also chelate tetracyclines. Take tetracycline 1 hour before or 2 hours after meals. Avoid alcohol (hepatotoxicity risk).
No direct food interactions. Avoid eating on the treated side to prevent dislodgement of the fiber. Maintain soft diet to minimize trauma. Avoid alcohol-based mouthwashes.
Tetracyclines, including Tetrachel, are classified as FDA Pregnancy Category D. They can cause fetal harm when administered to a pregnant woman. Use during the second and third trimesters (weeks 13 to 40) is associated with permanent discoloration of teeth (yellow-gray-brown) and enamel hypoplasia in the child. Additionally, there is a risk of retarded skeletal growth and potentially reversible inhibition of bone growth. Use during the first trimester is generally discouraged unless no alternative therapy is available, as there may be a small risk of teratogenicity (e.g., neural tube defects, cardiovascular malformations) based on some observational studies, though evidence is conflicting.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, reduced fetal weight) at doses 1-2 times the human dose. First trimester: potential for teratogenicity (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus; also potential for inhibition of fetal bone growth and maternal hepatotoxicity. Use only if potential benefit outweighs risk.
Tetracycline is excreted into human milk, with milk-to-plasma ratio (M/P) approximately 0.5-0.8. Low levels of tetracycline are found in breast milk; however, due to potential for serious adverse reactions (e.g., permanent tooth discoloration and bone growth inhibition) in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Alternative antibiotics with better safety profiles in lactation are preferred.
Tetracycline is excreted in human milk (M/P ratio approximately 0.6-1.5). Due to potential for serious adverse reactions (tooth discoloration, bone growth inhibition, photosensitivity) in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Avoid prolonged use during breastfeeding.
Due to physiological changes in pregnancy (increased plasma volume, increased renal clearance), tetracycline may achieve lower serum concentrations. However, specific dosing adjustment guidelines for tetracycline in pregnancy are not established. The drug is generally avoided in pregnancy, particularly after the first trimester. If use is necessary in the first trimester, standard dosing based on non-pregnant adults is typically used, but careful monitoring for efficacy and toxicity is recommended. No dose adjustment is recommended for hepatic or renal impairment in pregnancy as the drug is contraindicated in such conditions.
No specific dose adjustments for ACTISITE (tetracycline periodontal fiber). Systemic absorption minimal (peak serum concentrations <0.1 mcg/m L). Pregnancy may alter pharmacokinetics of tetracycline (increased volume of distribution, decreased protein binding), but due to local administration, systemic effects are negligible. No dosage adjustment required for the fiber formulation; however, avoid systemic tetracycline use during pregnancy when possible.
Tetracyclines are bacteriostatic antibiotics that inhibit protein synthesis. Avoid in children under 8 years and pregnant/breastfeeding women due to bone and tooth discoloration. Administer on an empty stomach (1 hour before or 2 hours after meals) with a full glass of water to prevent esophagitis. Do not take with dairy, antacids, or iron supplements as they chelate and reduce absorption. Photosensitivity risk: advise sun avoidance and sunscreen use.
ACTISITE (tetracycline hydrochloride) periodontal fiber is a controlled-release local antibiotic for adjunctive treatment of chronic periodontitis. Insert fiber into periodontal pocket to deliver drug over 10 days. Ensure pocket depth is ≥5mm. Do not use with metallic or synthetic fibers. Fiber must be secured with cyanoacrylate adhesive. Monitor for foreign body sensation, pain, or infection. Removal at 10 days is mandatory to avoid excessive tissue reaction. Not for acute abscesses.
Take this medication on an empty stomach with a full glass of water.,Avoid dairy products, antacids, and iron supplements within 2 hours of taking this drug.,Use sunscreen and protective clothing to prevent severe sunburn.,Complete the full course of therapy even if you feel better.,Report any signs of allergic reaction, severe headache, or vision changes immediately.
Do not brush or floss the treated area while the fiber is in place.,Avoid chewing hard or sticky foods on the treated side.,You may feel a mild foreign body sensation; report severe pain or swelling.,The fiber must be removed after 10 days; do not leave it longer.,Complete the full course of prescribed oral hygiene and antibiotics if given.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TETRACHEL vs ACTISITE, answered by our medical review team.
TETRACHEL is a Tetracycline Antibiotic that works by Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex.. ACTISITE is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TETRACHEL and ACTISITE depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TETRACHEL is: 500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.. The standard adult dose of ACTISITE is: Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TETRACHEL and ACTISITE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TETRACHEL is classified as Category C. Tetracyclines, including Tetrachel, are classified as FDA Pregnancy Category D. They can cause fetal harm when administered to a pregnant woman. Use during the second and third tri. ACTISITE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, red. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.